ELIGARD Pre-connected Syringe System Mixing & Administration

Keep control and reliability in your hands with just one CLICK

ELIGARD (leuprolide acetate) for injectable suspension 6-month, 45 mg dose

Mixing and administration of ELIGARD only requires

Prepare
Mix
Administer

Prepare

Allow the product to reach room temp.
59-86° F before using

Mix

Thoroughly mix the product for 60 cycles

Administer

Inject ELIGARD at a 90˚ angle into subcutaneous tissue

Storing ELIGARD

10.875" w x 3.2" h x 1.4" d

ELIGARD is a refrigerated product – however, once received, it can be stored at room temperature (59-86° F) for up to 8 weeks¹

Order ELIGARD

Direct via the phone or online through Besse Medical.

FORMULATION: ELIGARD 45 mg (6-month dose)

NDC Number:62935-461-50

(ELIGARD 45 mg, 6-month Pre-connected Syringe System only)

Now Available

ELIGARD 45 mg is an easy to mix Pre-Connected Syringe System allowing you to prepare and administer with more confidence.

Watch the Mixing and Administration video

Get the Mixing and Administration guide

See how easy it is to order ELIGARD Pre-Connected Syringe System

LEARN MORE >

Join our weekly virtual Mixing & Administration Training Sessions

Virtual Training Sessions include a demonstration on mixing and administering ELIGARD. The clinical trainer will answer any questions you may have.

IMPORTANT SAFETY INFORMATION

ELIGARD®, (leuprolide acetate) for injectable suspension, is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported. See package insert for full Prescribing and Safety Information.

Please see full Prescribing Information for ELIGARD or full Prescribing Information for ELIGARD Pre-Connected Syringe System.